As of Jul 25, 2024, the Gilead Sciences stock's PE ratio is 191.28. This results from the current EPS of $0.4 and stock price of $76.51. The current PE ratio is nearly equal to the average from the previous four quarters.
The PE ratio of Gilead Sciences has averaged 43.82 over the last ten years. The current PE ratio of 191.28 is comparable to the historical average. Over the past ten years, GILD's PE ratio was at its highest in the Dec 2020 quarter at 582.6, when the stock price was $58.26 and the EPS was $0.1. The lowest value was in the Dec 2016 quarter, when it reached 7.1 with a price of $71.61 and an EPS of $10.08.
Maximum annual increase: 3,700.39% in 2020
Maximum annual decrease: -97.49% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 17.84 | -23.96% |
| 2022 | 23.46 | 60.25% |
| 2021 | 14.64 | -97.49% |
| 2020 | 582.6 | 3,700.39% |
| 2019 | 15.33 | 2.96% |
| 2018 | 14.89 | -26.43% |
| 2017 | 20.24 | 185.07% |
| 2016 | 7.1 | -13.2% |
| 2015 | 8.18 | -31.03% |
| 2014 | 11.86 | -68.25% |
The current PE ratio of GILD is greater than its 3, 5 and 10-year historical averages.
Compared to its peer stocks LLY and JNJ, GILD's PE ratio stands higher. Gilead Sciences's current PE ratio of 191.28 is comparable to the average of its peer group, which is 34.37.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.55 | $386.7B |
| BIIB Biogen Inc | 26.23 | $30.75B |
| VRTX Vertex Pharmaceuticals Inc | 31.79 | $127.8B |
| AMGN Amgen Inc | 47.56 | $179.63B |
| ABBV AbbVie Inc | 54.94 | $326.97B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| MRK Merck & Co Inc | 137.65 | $317.26B |
| GILD Gilead Sciences Inc | 192.53 | $95.94B |
| ILMN Illumina Inc | N/A | $19.18B |
| PFE Pfizer Inc | N/A | $174.36B |
GILD stock has a price to earnings ratio of 191.28 as of Jul 25, 2024.
Over the last 3 years, the average price to earnings ratio for GILD stock is 32.85.
Over the last 5 years, the average price to earnings ratio for GILD stock is 74.89.
In the last ten years, the Dec 2020 quarter recorded the highest quarterly PE ratio at 582.6.
GILD's price to earnings ratio is currently 337% above its 10-year historical average.
A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 25, 2024), Gilead Sciences's stock price is $76.51. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $0.4. Therefore, Gilead Sciences's P/E ratio for today is 191.28. PE RATIO(191.28) = STOCK PRICE($76.51) / TTM EPS($0.4)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.